- Researchers report that medications that contain the ingredient trizepatide work to help people lose weight, no matter how long they have had weight problems.
- They say people should remain on these medications long-term for effective weight management because when they go off the drugs, their weight can return.
- They add that the results of the study show that it is never too late for people to try to lose weight.
Weight loss drugs that contain the ingredient trizepatide such as Mounjaro and Zepbound can help people lose weight and reduce their waist circumference, no matter how long they have had obesity or weight issues.
That’s according to research that will be presented at this year’s European Congress on Obesity in Venice, Italy, in May.
The findings have not been published yet in a peer-reviewed journal.
The U.S. Food and Drug Administration (FDA) has approved both medications — Mounjaro in 2022 for the treatment of type 2 diabetes and
Researchers used data from several studies using the SURMOUNT phase 3 trials.
In them, they compared tirzepatide medications to a group given a placebo against three other groups of people:
- Participants with obesity and at least one weight-related comorbidity that was not type 2 diabetes.
- Individuals with obesity and type 2 diabetes.
- People without type 2 diabetes after they had undergone a 12-week intensive lifestyle intervention or 36 weeks of tirzepatide.
Participants were also grouped based on the length of time they reported they had weight issues or obesity:
- 10 years or less
- Between 10 and 20 years
- More than 20 years
The scientists evaluated the percentage of change in body weight and waist circumference when participants achieved weight loss targets of 5%, 10%, 15%, 20%, and 25% of total body weight.
The findings included:
- Participants with weight/obesity issues for less than 10 years…
Read the full article here